Comerica Bank Grows Holdings in The Chemours Company $CC

Comerica Bank raised its position in The Chemours Company (NYSE:CC) by 13.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,738 shares of the specialty chemicals company’s stock after purchasing an additional 7,498 shares during the period. Comerica Bank’s holdings in Chemours were worth $876,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new position in shares of Chemours during the 1st quarter worth about $213,000. Channing Capital Management LLC lifted its holdings in shares of Chemours by 31.7% during the 1st quarter. Channing Capital Management LLC now owns 366,345 shares of the specialty chemicals company’s stock worth $4,957,000 after acquiring an additional 88,201 shares during the period. Bruce & Co. Inc. purchased a new position in shares of Chemours during the 1st quarter worth about $2,706,000. Capital Fund Management S.A. lifted its holdings in shares of Chemours by 103.5% during the 1st quarter. Capital Fund Management S.A. now owns 369,579 shares of the specialty chemicals company’s stock worth $5,000,000 after acquiring an additional 188,000 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Chemours during the 1st quarter worth about $591,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Chemours

In related news, CEO Denise Dignam purchased 4,068 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $12.06 per share, with a total value of $49,060.08. Following the completion of the transaction, the chief executive officer owned 191,546 shares of the company’s stock, valued at $2,310,044.76. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CC. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 27th. Morgan Stanley cut their price objective on shares of Chemours from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Monday, May 12th. Barclays cut their price objective on shares of Chemours from $16.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 28th. The Goldman Sachs Group dropped their target price on shares of Chemours from $21.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded shares of Chemours from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Chemours currently has a consensus rating of “Moderate Buy” and an average price target of $17.38.

Chemours Stock Up 3.7%

CC stock opened at $15.65 on Friday. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $22.38. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The company has a market capitalization of $2.34 billion, a P/E ratio of -5.59 and a beta of 1.61. The firm has a 50 day simple moving average of $13.73 and a 200-day simple moving average of $12.78.

Chemours (NYSE:CC) last released its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the company earned $0.38 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.2%. Chemours’s dividend payout ratio (DPR) is presently -12.50%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.